Marco Davila, Roswell Park SVP and associate director for translational research

Gen­er­a­tive AI biotech part­ners with can­cer cen­ter in bid to speed up CAR-T de­vel­op­ment in sol­id tu­mors

One of the biggest star­tups us­ing gen­er­a­tive AI to de­sign pro­tein-based ther­a­pies is bet­ting its tech­nol­o­gy may help crack one of the tough­est prob­lems in cell ther­a­py: get­ting CAR-T cells to tar­get sol­id tu­mors.

Gen­er­ate:Bio­med­i­cines an­nounced Wednes­day morn­ing that it struck a col­lab­o­ra­tion with Roswell Park Com­pre­hen­sive Can­cer Cen­ter in Buf­fa­lo, NY, to co-de­vel­op up to three CAR-T cell ther­a­pies for ovar­i­an can­cer and oth­er sol­id tu­mors. The two groups will equal­ly split the cost of de­sign­ing and de­vel­op­ing the treat­ments and any prof­its if they prove suc­cess­ful.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.